{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:13:22Z","timestamp":1788801202368,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda (English Edition)"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.anpede.2022.05.005","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T22:40:12Z","timestamp":1658270412000},"page":"130.e1-130.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Langerhans cell histiocytosis. Advances in pathogenesis and clinical practice"],"prefix":"10.1016","volume":"97","author":[{"given":"Itziar","family":"Astigarraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Garc\u00eda-Obreg\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Guti\u00e9rrez-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Santa-Mar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Rodr\u00edguez-Vigil","family":"Iturrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael Lorite","family":"Reggiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais Murciano","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Torrent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10295","key":"10.1016\/j.anpede.2022.05.005_bib0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(21)00311-1","article-title":"Histiocytosis","volume":"398","author":"Emile","year":"2021","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.anpede.2022.05.005_bib0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41572-021-00307-9","article-title":"Histiocytic disorders","volume":"7","author":"McClain","year":"2021","journal-title":"Nat Rev Dis Primers."},{"issue":"22","key":"10.1016\/j.anpede.2022.05.005_bib0015","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.anpede.2022.05.005_bib0020","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMra1607548","article-title":"Langerhans-cell histiocytosis","volume":"379","author":"Allen","year":"2018","journal-title":"N Engl J Med."},{"issue":"16","key":"10.1016\/j.anpede.2022.05.005_bib0025","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1182\/blood.2019000934","article-title":"Langerhans cell histiocytosis","volume":"135","author":"Rodriguez-Galindo","year":"2020","journal-title":"Blood."},{"issue":"Suppl 1","key":"10.1016\/j.anpede.2022.05.005_bib0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hon.2857","article-title":"Langerhans cell histiocytosis: version 2021","volume":"39","author":"Gulati","year":"2021","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.anpede.2022.05.005_bib0035","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.anpede.2022.05.005_bib0040","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood-2007-08-106211","article-title":"Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification","volume":"111","author":"Gadner","year":"2008","journal-title":"Blood."},{"issue":"25","key":"10.1016\/j.anpede.2022.05.005_bib0045","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","article-title":"Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","volume":"121","author":"Gadner","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.anpede.2022.05.005_bib0050","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/ITT.S91058","article-title":"Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies","volume":"5","author":"Hutter","year":"2016","journal-title":"Immunotargets Ther."},{"issue":"5","key":"10.1016\/j.anpede.2022.05.005_bib0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.arcped.2019.05.015","article-title":"Progress towards molecular-based management of childhood Langerhans cell histiocytosis","volume":"26","author":"H\u00e9ritier","year":"2019","journal-title":"Arch Pediatr."},{"issue":"10","key":"10.1016\/j.anpede.2022.05.005_bib0060","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1084\/jem.20030137","article-title":"Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis","volume":"197","author":"Annels","year":"2003","journal-title":"J Exp Med."},{"key":"10.1016\/j.anpede.2022.05.005_bib0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cyto.2017.05.026","article-title":"Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis","volume":"97","author":"Morimoto","year":"2017","journal-title":"Cytokine."},{"issue":"11","key":"10.1016\/j.anpede.2022.05.005_bib0070","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood."},{"issue":"25","key":"10.1016\/j.anpede.2022.05.005_bib0075","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","article-title":"BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy","volume":"34","author":"H\u00e9ritier","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.anpede.2022.05.005_bib0080","series-title":"editores. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised","author":"Swerdlow","year":"2017"},{"issue":"4","key":"10.1016\/j.anpede.2022.05.005_bib0085","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.20130977","article-title":"BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups","volume":"211","author":"Berres","year":"2014","journal-title":"J Exp Med."},{"issue":"10","key":"10.1016\/j.anpede.2022.05.005_bib0090","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2014-05-577361","article-title":"High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis","volume":"124","author":"Brown","year":"2014","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.anpede.2022.05.005_bib0095","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s12519-019-00304-9","article-title":"Childhood Langerhans cell histiocytosis: a disease with many faces","volume":"15","author":"Leung","year":"2019","journal-title":"World J Pediatr"},{"issue":"9","key":"10.1016\/j.anpede.2022.05.005_bib0100","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1517\/14656566.2012.688028","article-title":"Medical management of Langerhans cell histiocytosis from diagnosis to treatment","volume":"13","author":"Donadieu","year":"2012","journal-title":"Expert Opin Pharmacother."},{"issue":"2","key":"10.1016\/j.anpede.2022.05.005_bib0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/pbc.24367","article-title":"Langerhans Cell Histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years","volume":"60","author":"Haupt","year":"2013","journal-title":"Pediatr Blood Cancer."},{"issue":"6","key":"10.1016\/j.anpede.2022.05.005_bib0110","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2017.05.060","article-title":"Langerhans cell histiocytosis in children. Diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up","volume":"78","author":"Krooks","year":"2018","journal-title":"J Am Acad Dermatol."},{"issue":"10","key":"10.1016\/j.anpede.2022.05.005_bib0115","doi-asserted-by":"crossref","first-page":"643","DOI":"10.5435\/JAAOS-22-10-643","article-title":"Diagnosis and management of Langerhans cell histiocytosis","volume":"22","author":"DiCaprio","year":"2014","journal-title":"J Am Acad Orthop Surg."},{"issue":"1","key":"10.1016\/j.anpede.2022.05.005_bib0120","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13046-019-1094-2","article-title":"Clinical development of targeted and immune based anti-cancer therapies","volume":"38","author":"Seebacher","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"issue":"3","key":"10.1016\/j.anpede.2022.05.005_bib0125","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14695","article-title":"Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis","volume":"178","author":"H\u00e9ritier","year":"2017","journal-title":"Br J Haematol."},{"issue":"15","key":"10.1016\/j.anpede.2022.05.005_bib0130","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2018-10-878363","article-title":"Clinical responses and persistent BRAF V600E1 blood cells in children with LCH treated with MAPK pathway inhibition","volume":"133","author":"Eckstein","year":"2019","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.anpede.2022.05.005_bib0135","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28034","article-title":"FDG PET-TC in pediatric Langerhans cell histiocitosis","volume":"67","author":"Jessop","year":"2020","journal-title":"Pediatr Blood Cancer."},{"issue":"5","key":"10.1016\/j.anpede.2022.05.005_bib0140","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jpeds.2014.07.063","article-title":"Differentiating skin-limited and multisystem Langerhans cell histiocytosis","volume":"165","author":"Simko","year":"2014","journal-title":"J Pediatr."},{"issue":"3","key":"10.1016\/j.anpede.2022.05.005_bib0145","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/pbc.25834","article-title":"Diverse cutaneous presentations of Langerhans cell histiocytosis in children: a retrospective cohort study","volume":"63","author":"Morren","year":"2016","journal-title":"Pediatr Blood Cancer."},{"issue":"1","key":"10.1016\/j.anpede.2022.05.005_bib0150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2014-12-569301","article-title":"How I treat Langerhans cell histiocytosis","volume":"126","author":"Allen","year":"2015","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.anpede.2022.05.005_bib0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.paed.2015.10.009","article-title":"Advances in the understanding and management of histiocytic disorders 2015","volume":"26","author":"Windebank","year":"2016","journal-title":"Paediatr Child Health."},{"issue":"12","key":"10.1016\/j.anpede.2022.05.005_bib0160","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1002\/pbc.25645","article-title":"Management and outcome of patients with Langerhans cell histiocytosis and single-bone CNS-risk lesions: a multi-institutional retrospective study","volume":"62","author":"Chellapandian","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"20","key":"10.1016\/j.anpede.2022.05.005_bib0165","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood-2016-06-721993","article-title":"Hydroxyurea: a new old therapy for Langerhans cell histiocytosis","volume":"128","author":"Zinn","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.anpede.2022.05.005_bib0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10195-016-0434-7","article-title":"Current concepts for the diagnosis and management of eosinophilic granuloma of bone","volume":"18","author":"Angelini","year":"2017","journal-title":"J Orthop Traumatol."},{"issue":"5","key":"10.1016\/j.anpede.2022.05.005_bib0175","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1097\/MPH.0000000000000165001","article-title":"Symptomatic bone Langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone","volume":"36","author":"Braier","year":"2014","journal-title":"J Pediatr Hematol Oncol."},{"issue":"5","key":"10.1016\/j.anpede.2022.05.005_bib0180","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1111\/bjh.17067","article-title":"Indomethacin is an effective treatment in adults and children with bone Langerhans cell histiocytosis (LCH)","volume":"191","author":"De Benedittis","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anpede.2022.05.005_bib0185","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jpeds.2021.06.016","article-title":"Additive prognostic impact of gastrointestinal involvement in severe multisystem Langerhans cell histiocytosis","volume":"237","author":"Minkov","year":"2021","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.anpede.2022.05.005_bib0190","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/pbc.20021","article-title":"Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the histiocyte society-late effects study group","volume":"42","author":"Haupt","year":"2004","journal-title":"Pediatr Blood Cancer."},{"issue":"31","key":"10.1016\/j.anpede.2022.05.005_bib0195","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.19.00456","article-title":"Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study","volume":"37","author":"Donadieu","year":"2019","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.anpede.2022.05.005_bib0200","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26784","article-title":"Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas","volume":"65","author":"Yeh","year":"2018","journal-title":"Pediatr Blood Cancer."}],"container-title":["Anales de Pediatr\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S234128792200148X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S234128792200148X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:45:20Z","timestamp":1762422320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S234128792200148X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S234128792200148X"],"URL":"https:\/\/doi.org\/10.1016\/j.anpede.2022.05.005","relation":{},"ISSN":["2341-2879"],"issn-type":[{"value":"2341-2879","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Langerhans cell histiocytosis. Advances in pathogenesis and clinical practice","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anpede.2022.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.anpedi.2022.05.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}